Document Detail


Reovirus: a targeted therapeutic--progress and potential.
MedLine Citation:
PMID:  23038811     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Medical therapy of patients with malignancy requires a paradigm shift through development of new drugs with a good safety record and novel mechanisms of activity. While there is no dearth of such molecules, one particular agent, "reovirus" is promising by its ability to target cancer cells with aberrant signaling pathways. This double-stranded RNA virus has been therapeutically formulated and has rapidly progressed from preclinical validation of anticancer activity to a phase III registration study in platinum refractory metastatic squamous cell carcinoma of the head and neck. During this process, reovirus has shown safety both as a single agent when administered intratumorally and intravenously, as well as in combination therapy, with multiple chemotherapeutics such as gemcitabine, carboplatin/paclitaxel, and docetaxel; and similarly with radiation. The scientific rationale for its development as an anticancer agent stems from the fact that it preferentially replicates in and induces lyses of cells with an activated Kras pathway. As documented in many previous studies, the initial observation of greater tropism in Kras-compromised situation might certainly not be the sole and possibly not even the predominant reason for enhanced virulence. All the same, scientists have emphasized on Kras optimistically due to its high prevalence in various types of cancers. Incidence of Kras mutation has been found to be highest in pancreatic cancer (85%-90%) followed by colorectal (35-45%) and lung (25-30%). Reovirus, in fact has the potential not only as a therapy but also as a tool to unravel the aberrant cellular pathway leading to carcinogenicity.
Authors:
Radhashree Maitra; Mohammad H Ghalib; Sanjay Goel
Publication Detail:
Type:  Journal Article; Review     Date:  2012-10-04
Journal Detail:
Title:  Molecular cancer research : MCR     Volume:  10     ISSN:  1557-3125     ISO Abbreviation:  Mol. Cancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-21     Completed Date:  2013-09-03     Revised Date:  2013-12-11    
Medline Journal Info:
Nlm Unique ID:  101150042     Medline TA:  Mol Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1514-25     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials, Phase III as Topic
Humans
Neoplasms / genetics,  therapy*,  virology*
Oncolytic Virotherapy / methods*
Reoviridae / genetics*
Grant Support
ID/Acronym/Agency:
K12 CA132783/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alkylation sensitivity screens reveal a conserved cross-species functionome.
Next Document:  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type p...